High costs, long durations, and regulatory complexity concentrate innovation in wealthy nations.
The Problem
Addressing Critical Unmet Medical Needs
Key Challenges
Limited capacity and misaligned incentives constrain therapeutic development at current costs.
Rare and neglected diseases receive limited focus while access and affordability remain uneven.
The Scale of the Problem
9,000+
Identified diseases
~90%
Diseases without approved therapies
400M+
People with rare diseases globally
$8T
US direct and indirect rare disease costs
$240k/yr
Average US rare disease treatment cost
Understanding the Impact
New drug development requires significant capital and faces uncertain recovery of sunk costs. The result is a narrow focus on profitable widespread indications, widening disparities in access and affordability and creating systemic inefficiencies in care.
There Is a Better Way
LADR addresses these fundamental challenges by reducing time, cost, and risk while improving the probability that promising therapies can reach patients.
4x Faster
Develop approximately 4x faster as compared to de novo drug development.
~5% Cost
~5% of cost as compared to de novo drug development.
Higher Success Rate
Higher probability of success as compared to de novo drug development.